DENTSPLY SIRONA Inc. Common Stock (XRAY)

FairStock Score: 58/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look at DENTSPLY SIRONA as a dental equipment and consumables business with an installed base and recurring demand, but the numbers do not yet show a durable moat. Revenue in the filed accounts fell from $4.0B in fiscal year 2023 to $3.7B in fiscal year 2025, and the company reported net losses of $132.0M, $910.0M, and $598.0M in those years. The latest filed quarter, fiscal Q2 2026 ended 2026-06-30, did earn $37.0M on $898.0M of revenue, a 4.12% margin, but one quarter does not erase four years of red ink or the Lynch category of none because of losses in each of the last four years. Financial health is the weak link: debt-to-equity is 1.72 and the Altman Z-Score is 0.25, a FairStock calculation that signals distress. Returns are poor, with ROCE of 1.96%. The positives are cash generation and price: trailing free cash flow is $143.0M, a FairStock 8.4% FCF yield on the $1.7B market cap, and the shares at $8.51 on 2026-10-13 trade at 1.29 times book and near the 52-week low of $8.38. A Piotroski F-Score of 9/9 offers hope, but FairStock's EV/EBITDA of 40.53 and negative P/E of -3.12 show how fragile earnings are. I would want to see several quarters of real profit, lower debt, and stable revenue before trusting this as a value recovery.

In plain English: DENTSPLY SIRONA makes dental equipment and supplies, along with some medical products. The business has lost money in each of the last four years, carries a lot of debt, and its sales have slipped, though it earned a small profit in the most recent quarter. At $8.51, the stock looks cheap compared with its accounting assets, but the weak profits and high debt make it risky and hard to call healthy.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer